UAB To Test Potential COVID-19 Vaccine

 ========= Old Image Removed =========Array
(
    [_wp_attached_file] => Array
        (
            [0] => 2020/03/COVIDresearch2-e1585604335787.jpg
        )

    [_wp_attachment_metadata] => Array
        (
            [0] => a:5:{s:5:"width";i:600;s:6:"height";i:337;s:4:"file";s:41:"2020/03/COVIDresearch2-e1585604335787.jpg";s:5:"sizes";a:8:{s:9:"thumbnail";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-140x140.jpg";s:5:"width";i:140;s:6:"height";i:140;s:9:"mime-type";s:10:"image/jpeg";}s:6:"medium";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-336x189.jpg";s:5:"width";i:336;s:6:"height";i:189;s:9:"mime-type";s:10:"image/jpeg";}s:9:"wbhm-icon";a:4:{s:4:"file";s:39:"COVIDresearch2-e1585604335787-80x80.jpg";s:5:"width";i:80;s:6:"height";i:80;s:9:"mime-type";s:10:"image/jpeg";}s:13:"wbhm-featured";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-600x337.jpg";s:5:"width";i:600;s:6:"height";i:337;s:9:"mime-type";s:10:"image/jpeg";}s:20:"wbhm-featured-square";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-300x300.jpg";s:5:"width";i:300;s:6:"height";i:300;s:9:"mime-type";s:10:"image/jpeg";}s:18:"wbhm-featured-home";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-554x311.jpg";s:5:"width";i:554;s:6:"height";i:311;s:9:"mime-type";s:10:"image/jpeg";}s:22:"wbhm-featured-carousel";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-470x265.jpg";s:5:"width";i:470;s:6:"height";i:265;s:9:"mime-type";s:10:"image/jpeg";}s:14:"post-thumbnail";a:4:{s:4:"file";s:41:"COVIDresearch2-e1585604335787-125x125.jpg";s:5:"width";i:125;s:6:"height";i:125;s:9:"mime-type";s:10:"image/jpeg";}}s:10:"image_meta";a:12:{s:8:"aperture";s:3:"2.8";s:6:"credit";s:12:"Getty Images";s:6:"camera";s:9:"ILCE-7RM3";s:7:"caption";s:71:"Back view of Scientist testing Vaccine Coronavirus in Biosafety Cabinet";s:17:"created_timestamp";s:10:"1583682993";s:9:"copyright";s:0:"";s:12:"focal_length";s:2:"32";s:3:"iso";s:3:"320";s:13:"shutter_speed";s:4:"0.01";s:5:"title";s:71:"Back view of Scientist testing Vaccine Coronavirus in Biosafety Cabinet";s:11:"orientation";s:1:"1";s:8:"keywords";a:0:{}}}
        )

    [_media_credit] => Array
        (
            [0] => The University of Alabama at Birmingham
        )

    [_navis_media_credit_org] => Array
        (
            [0] => 
        )

    [_navis_media_can_distribute] => Array
        (
            [0] => 
        )

    [_wp_attachment_backup_sizes] => Array
        (
            [0] => a:9:{s:9:"full-orig";a:3:{s:5:"width";i:600;s:6:"height";i:451;s:4:"file";s:18:"COVIDresearch2.jpg";}s:14:"thumbnail-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-140x140.jpg";s:5:"width";i:140;s:6:"height";i:140;s:9:"mime-type";s:10:"image/jpeg";}s:11:"medium-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-336x253.jpg";s:5:"width";i:336;s:6:"height";i:253;s:9:"mime-type";s:10:"image/jpeg";}s:14:"wbhm-icon-orig";a:4:{s:4:"file";s:24:"COVIDresearch2-80x80.jpg";s:5:"width";i:80;s:6:"height";i:80;s:9:"mime-type";s:10:"image/jpeg";}s:18:"wbhm-featured-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-600x338.jpg";s:5:"width";i:600;s:6:"height";i:338;s:9:"mime-type";s:10:"image/jpeg";}s:25:"wbhm-featured-square-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-300x300.jpg";s:5:"width";i:300;s:6:"height";i:300;s:9:"mime-type";s:10:"image/jpeg";}s:23:"wbhm-featured-home-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-414x311.jpg";s:5:"width";i:414;s:6:"height";i:311;s:9:"mime-type";s:10:"image/jpeg";}s:27:"wbhm-featured-carousel-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-353x265.jpg";s:5:"width";i:353;s:6:"height";i:265;s:9:"mime-type";s:10:"image/jpeg";}s:19:"post-thumbnail-orig";a:4:{s:4:"file";s:26:"COVIDresearch2-125x125.jpg";s:5:"width";i:125;s:6:"height";i:125;s:9:"mime-type";s:10:"image/jpeg";}}
        )

)
1618857163 
1585586365

By BirminghamWatch

The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.

Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.

The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.

The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”

“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.

Lund said six labs at UAB will work on the project.

Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.

“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.

UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.

“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.

 

The Gulf States Newsroom is hiring a Community Engagement Producer

The Gulf States Newsroom is seeking a curious, creative and collaborative professional to work with our regional team to build up engaged journalism efforts.

Gambling bills face uncertain future in the Alabama legislature

This year looked to be different for lottery and gambling legislation, which has fallen short for years in the Alabama legislature. But this week, with only a handful of meeting days left, competing House and Senate proposals were sent to a conference committee to work out differences.

Alabama’s racial, ethnic health disparities are ‘more severe’ than other states, report says

Data from the Commonwealth Fund show that the quality of care people receive and their health outcomes worsened because of the COVID-19 pandemic.

What’s your favorite thing about Alabama?

That's the question we put to those at our recent News and Brews community pop-ups at Hop City and Saturn in Birmingham.

Q&A: A former New Orleans police chief says it’s time the U.S. changes its marijuana policy

Ronal Serpas is one of 32 law enforcement leaders who signed a letter sent to President Biden in support of moving marijuana to a Schedule III drug.

How food stamps could play a key role in fixing Jackson’s broken water system

JXN Water's affordability plan aims to raise much-needed revenue while offering discounts to customers in need, but it is currently tied up in court.

More BirminghamWatch Coverage